Loading clinical trials...

Safety and Efficacy Study Comparing ProDisc-C to ACDF Surgery to Treat SCDD | Clinical Trials | Clareo Health

COMPLETEDNA

Safety and Efficacy Study Comparing ProDisc-C to ACDF Surgery to Treat SCDD

A Multi-Center, Prospective, Randomized, Controlled Clinical Trial Comparing the Safety and Effectiveness of ProDisc-C to Anterior Cervical Discectomy and Fusion (ACDF) Surgery in the Treatment of Symptomatic Cervical Disc Disease (SCDD)

NCT00291018•Synthes USA HQ, Inc.

View on ClinicalTrials.gov

Summary

The objective of this clinical investigation is to compare the safety and effectiveness of ProDisc-C to anterior cervical discectomy and fusion (ACDF) surgery in the treatment of symptomatic cervical disc disease (SCDD).

Eligibility

Age

18 - 60 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Symptomatic cervical disc disease (SCDD) in one vertebral level between C3-C7 defined as: Neck or arm (radicular) pain; and/or a functional/neurological deficit with at least one of the following conditions confirmed by imaging (CT, MRI or X-rays): Herniated nucleus pulposus; Spondylosis (defined by the presence of osteophytes); and/or Loss of disc height.
•Age between 18 and 60 years.
•Unresponsive to non-operative treatment for approximately six weeks or has the presence of progressive symptoms or signs of nerve root/spinal cord compression in the face of conservative treatment.
•NDI score greater than or equal to 15/50 (30%).
•Psychosocially, mentally and physically able to fully comply with the protocol including adhering to follow-up schedule and requirements and filling out forms.
•Signed informed consent.

Exclusion Criteria

•More than one vertebral level requiring treatment.
•Marked cervical instability on resting lateral or flexion/extension radiographs: translation greater than 3mm and/or greater than 11 degrees of rotational difference to that of either adjacent level.
•Has a fused level adjacent to the level to be treated.
•Radiographic confirmation of severe facet joint disease or degeneration.
•Known allergy to cobalt, chromium, molybdenum, titanium or polyethylene.
•Clinically comprised vertebral bodies at the affected level(s) due to current or past trauma, e.g. by the radiographic appearance of fracture callus, malunion or nonunion.
•Prior surgery at the level to be treated.
•Severe spondylosis at the level to be treated as characterized by any of the following: Bridging osteophytes; A loss of disc height greater than 50%; or Absence of motion (\<2°).
•Neck or arm pain of unknown etiology.
•Osteoporosis: A screening questionnaire for osteoporosis, SCORE (Simple Calculated Osteoporosis Risk Estimation), will be used to screen patients who require a DEXA (dual energy x-ray absoptiometry) bone mineral density measurement. If DEXA is required, exclusion will be defined as a DEXA bone density measured T score less than or equal to -2.5 (the World Health Organization definition of osteoporosis).
+8 more criteria

Key Dates

Start Date

August 1, 2003

Primary Completion Date

March 1, 2015

Completion Date

March 1, 2015

Last Updated

November 20, 2017

Enrollment

368

ACTUAL participants

Conditions

Symptomatic Cervical Disc Disease

Interventions

Total Disc Replacement

DEVICE

ACDF

DEVICE